EnVision Endoscopy, a Massachusetts-based medical device startup developing novel endoscopic suturing and tissue-approximation technologies for gastrointestinal surgery, has raised approximately $4 million across a series of grant and early-stage investment rounds as it advances toward clinical validation and commercialization of its minimally invasive surgical platform.

The company, founded by Dr. Azadeh Khanicheh and Dr. Christopher Thompson, is focused on building an Image Guided Suturing System (IGSS) designed to improve flexible endoscopy procedures and enable safer, more effective closure of large gastrointestinal defects. Its technology aims to reduce the need for open surgery by allowing complex tissue repair to be performed through endoscopic tools, addressing a major unmet need in gastrointestinal care.

A significant portion of EnVision Endoscopy’s funding has come through non-dilutive federal and state-supported programs. The company was awarded approximately $999,952 through the U.S. National Science Foundation’s SBIR Phase II program, which supports commercialization of deep-tech biomedical innovations moving from research into clinical application. This funding has helped support development of its core suturing platform and preclinical validation work.

In addition to federal support, EnVision Endoscopy has received multiple rounds of grant funding from the Commonwealth of Massachusetts through MassVentures, including participation in the SBIR Targeted Technologies (START) program. MassVentures, the state’s strategic venture capital arm, has provided both capital and commercialization support to help the company transition its research into a viable medical product. MassVentures has been a recurring backer across several of the company’s grant cycles, including awards ranging from roughly $500,000 down to earlier-stage $100,000–$500,000 support packages.

The company has also participated in accelerator and early venture programs, including an accelerator-style investment round reported in 2019 valued at roughly $75,000, reflecting its earliest institutional backing stage. These early funds were used to advance prototype development and establish foundational intellectual property around its endoscopic suturing system.

Overall, EnVision Endoscopy has raised more than $3.9 million across approximately a dozen funding events, including grants, convertible notes, and early venture participation rounds. According to publicly available funding records, its capital structure has been heavily weighted toward non-dilutive grant funding, a common pattern for early-stage medical device startups operating in the regulatory-intensive healthcare sector.

The company’s investor base is primarily composed of public-sector innovation programs rather than traditional venture capital firms. Alongside MassVentures and the NSF, EnVision Endoscopy has benefited from broader U.S. innovation funding initiatives designed to support medical technology translation from academic research into clinical deployment. These programs have provided both financial support and validation milestones required for later-stage regulatory progress.

As part of its development roadmap, EnVision Endoscopy is preparing for expanded preclinical studies and early clinical evaluations of its suturing platform. The company’s system is designed to integrate with flexible endoscopy workflows, enabling physicians to perform complex gastrointestinal repairs without open surgery or traditional laparoscopic intervention.

The broader market opportunity for EnVision Endoscopy lies in the growing demand for minimally invasive surgical tools, particularly in gastrointestinal care where complications such as perforations, leaks, and post-operative defects remain difficult to treat endoscopically. By combining imaging guidance with precision suturing capabilities, the company aims to improve patient outcomes while reducing hospital stays and procedural costs.

With continued support from government-backed innovation programs such as the National Science Foundation and Massachusetts-based venture initiatives like MassVentures, EnVision Endoscopy remains positioned in the early commercialization phase of its development. The company is expected to continue leveraging grant funding and strategic public-sector investment as it moves toward regulatory submission and potential clinical adoption of its technology.

Related Articles